Effect of Nutritional Supplementation and Pulmonary Rehabilitation on the Clinical Status of HF and COPD
NCT ID: NCT04432194
Last Updated: 2020-06-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-08-30
Study Completion Date
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cardiovascular diseases (CVD) are the leading cause of death in the world and our country. The prevalence of Heart Failure (HF) is 1-2% in the adult population in developed countries, up to 10% among people 70 years of age. Concerning COPD, it is estimated that by 2030 will be the third leading cause of death in the world; the prevalence in Mexico is 18.4%. Also, according to INEGI data, it is the 5th cause of death in people over 65.
50% of patients with COPD die of cardiovascular causes, and they are at higher risk of developing HF, hospital readmissions, and death.
Subjects with HF and COPD concomitant have alterations such as; systemic inflammation, loss of muscle mass and strength of both skeletal and respiratory muscles, reduced tolerance to exercise, and lung function, which has an important impact on clinical status, quality of life and prognosis.
The objective of nutritional treatment in HF is to reduce heart overload and reduce cardiovascular risk. On the other hand, in COPD, it is to improve lung function. However, this is not enough to maintain the protein reserves of patients due to previously affected factors. Therefore, it is vitally essential to contemplate the supplementation with amino acids that prevent and delay the loss of protein reserves, as well as the delay in clinical status.
The β-hydroxy-β-methyl butyrate (HMB) is a metabolite of leucine, with an anticatabolic and anabolic effect. HMB improves the synthesis of proteins, muscle mass, strength, and muscle functionality. Citrulline has been associated with increased muscle mass, VO2, and exercise tolerance.
On the other hand, pulmonary rehabilitation (RP) has improved exercise tolerance, mass, and strength of skeletal and respiratory muscles, quality of life, reduction of hospitalizations, and mortality. However, in concomitant HF and COPD, there are no guidelines that specify the type of RP or if there is a synergistic effect with nutritional supplementation and its impact on clinical status.
50% of patients with COPD die of cardiovascular causes, and they are at higher risk of developing HF, hospital readmissions, and death.
Subjects with HF and COPD concomitant have alterations such as; systemic inflammation, loss of muscle mass and strength of both skeletal and respiratory muscles, reduced tolerance to exercise, and lung function, which has an important impact on clinical status, quality of life and prognosis.
The objective of nutritional treatment in HF is to reduce heart overload and reduce cardiovascular risk. On the other hand, in COPD, it is to improve lung function. However, this is not enough to maintain the protein reserves of patients due to previously affected factors. Therefore, it is vitally essential to contemplate the supplementation with amino acids that prevent and delay the loss of protein reserves, as well as the delay in clinical status.
The β-hydroxy-β-methyl butyrate (HMB) is a metabolite of leucine, with an anticatabolic and anabolic effect. HMB improves the synthesis of proteins, muscle mass, strength, and muscle functionality. Citrulline has been associated with increased muscle mass, VO2, and exercise tolerance.
On the other hand, pulmonary rehabilitation (RP) has improved exercise tolerance, mass, and strength of skeletal and respiratory muscles, quality of life, reduction of hospitalizations, and mortality. However, in concomitant HF and COPD, there are no guidelines that specify the type of RP or if there is a synergistic effect with nutritional supplementation and its impact on clinical status.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Effects of Pulmonary Rehabilitation in COPD
NCT03943030
Chronic Obstructive Pulmonary Disease
COMPLETED
NA
Nutritional Supplementation in Adults With Chronic Respiratory Disease
NCT02102009
Malnutrition
Pulmonary Disease, Chronic Obstructive
Other Pulmonary Disease, Chronic Obstructive
COMPLETED
NA
Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life
NCT07205627
Lung Disease Interstitial Diffuse
NOT_YET_RECRUITING
NA
"Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis"
NCT06105073
Systemic Sclerosis Associated Interstitial Lung Disease
UNKNOWN
The Impact of Pulmonary Rehabilitation on Dyspnea in Chronic Obstructive Pulmonary Disease
NCT01513616
Chronic Obstructive Pulmonary Disease
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Heart Failure
Heart Failure (HF) is a complex syndrome consequence of any structural or functional abnormality that impairs the capacity of filling or ejected of the heart. (1, 2).
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a progressive, systemic, and multi-organic disease with structural and functional changes, mostly in the lungs. It is characterized by a progressive limitation of airflow as a response to external factors such as airflow contamination, smoking, biomass, which are associated with chronic inflammation. (3).
Epidemiology
The cardiovascular disease is the leading cause of death worldwide (4); The HF prevalence goes from 1-2% in developed countries and increases to 10% in older \>70 years old.
COPD is an important global load affecting more than 600 million people corresponding to the 5 % off all cause of death worldwide (5).
Chronic Obstructive Pulmonary Disease and Heart Failure
COPD and HF are related between them, sharing the same risk factors and pathogenic mechanisms. They are growing in time and are epidemic diseases because of multiple factors. The cardiovascular disease takes an essential role in COPD, 30 to 50% of deaths are because of them; one of the most important is HF. COPD patients have three times the risk to developed HF (6), and between them, the risk of hospital readmission and death is higher than those without HF (7).
Nutritional Supplementation
β-Hydroxy-β-Methylbutyrate (HMB) HMB is a leucine metabolite, are a branch chain amino acid, and a regular potent in the muscular protein replacement and endogen sub-production that occurs in the muscles and liver. The first stage of change is through the transamination of the leucine to KIC, occurring in the mitochondrial and cytosol of the muscular cell. In the mitochondria, the KIC oxidates into isovaril-CoA, subsequently by other metabolism processes, it produces 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). Approximately 90% of KIC oxidize into isovaril CoA in the hepatic mitochondrial, lastly, acetoacetate and Acetyl-CoA. While the last 10% oxides into HMB in the cellular cytosol (8-10).
Supplementation with HMB
HMB develops a nutritional role; the daily supplementation has an anti-catabolic effect in the protein synthesis, increasing the muscular mass and diminished the muscular damage in adulthood.
Several studies evaluate the effects of supplementation with HMB, isolated, or combined in muscle functionality, strength, mortality, and indifferent pathologies(11). Recently, in a meth analysis and systemic review of randomized clinical trials made by Wu et al. to evaluate the effect of the administration with HMB over the corporal composition and muscular strength in adulthood in 65 years with pathologies. The study includes supplementation of HMB at 3mg doses at least eight weeks to increase the muscular strength and functionality (12). Supplementation with Ca-HMB with or without resistance exercise in older than 75 years' old was evaluated by Stout et al., in a pilot study, they made 2 phases: the first one (without exercise) supplementation with 3g of CaHMB vs. placebo and the second (with resistance exercise) with and without supplementation. They observed that the supplementation in the long term has better benefits, and increase lean mass, strength, quality, and functional muscle without exercise. In this study, they showed that there is no synergic effect with the exercise combined with supplementation (10).
Citrulline-arginine The principal precursor of citrulline is glutamine, representing 60% of the total synthesis of arginine de novo (13). Citrulline is released into the portal circulation because the enterocytes do not have the succinate arginine synthase. The liver absorbs one quantity in a normal hepatic function and goes to the systemic circulation and finally is transformed by the kidney into arginine (14). The supplementation is a potent nutrient-drug that helps to restore the arginine metabolism in different populations (14, 15).
Citrulline is considered a safe supplementation (16)with a maximum consumption of 15g/day and 13 g/day for arginine (17, 18). The blood levels in a healthy individual are 40 µmol/L (19). L citrulline increases the concentration of L arginine more efficiently than the supplementation of L-arginine; this is an amino acid, endogen precursor of the synthesis of oxide nitric (ON) (20).
Different studies with supplementation show a reduction in adhesion cells and leucocyte activation, as well as an improvement in endothelial function (21). Besides, in heathier subjects, it has been associated with less muscular fatigue, better VO2, and exercise tolerance. (22) In a randomized clinical trial (RCT) with healthy subjects, where they receive oral supplementation with citrulline, they showed an increase of 57% of the nitrogen balance 12 hrs. after (17)
Pulmonary rehabilitation
Pulmonary rehabilitation and physic therapy are essential components of the non-pharmacologic treatment, for HF and COPD, the guidelines' treatment recommends the pulmonary rehabilitation or physic therapy, to improve the exercise tolerance, skeletal and respiratory muscular function, also the quality of life of the patients (23, 24). On the other side, it has been demonstrated that pulmonary rehabilitation and physic therapy have benefits in the number of hospitalization and mortality of patients.
Ancanfora et al., in a randomized clinical trial evaluate the effect of cardiovascular training in patients with HF. The program consists of resistance activities and abdominal exercises, depending on the clinical characteristics of each patient, they were followed by four weeks, resulting in an improvement over-exercise tolerance, O2 maximum consumes and ventilatory threshold (25). Similarly, Keteyian et al., evaluated the physiological adaptation resulting by the physical training in patients with HF with Left ventricle ejection fraction. Also reduced the effects and security in clinical results, had a followed of 2-5 weeks, it consists by resistance exercises such as walking and the use of the static bicycle by 20-30 minutes (23). They conclude that the exercise was secure and improves the state of health, exercise capacity. O´connor et al., evaluated the effects of a regular aerobic exercise (bicycle, treadmill) in patients with HF plus the habitual care, followed by 30 months, they observed that the mortality and hospitalization decreases (26).
Additionally, Benefits have also been seen in patients with COPD; Petersen et al., after seven weeks, show that the resistance exercises twice a week improved exercise tolerance and diminished the fast degradation of proteins (27). Nevertheless, patients with HF and COPD have no guidelines that specified the type of exercise as well as the duration of it, or if there is a synergic effect with nutritional supplementation and which is the impact over the clinic stage.
General objective:
To assess the effect of nutritional supplementation and pulmonary rehabilitation on the clinical status of patients with HF and COPD compared to those subjects who do not receive nutritional supplementation or pulmonary rehabilitation.
Specific objectives
To evaluate the effect of pulmonary rehabilitation and supplementation over body composition in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over the exercise tolerance in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over pulmonary function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over endothelial function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over muscle function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over cognitive function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
Evaluated the effect of nutritional supplementation and pulmonary rehabilitation over prognosis in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
Hypothesis Subjects with HF and COPD who receive nutritional supplementation and pulmonary rehabilitation will have a better clinical status than those who do not receive nutritional supplementation or pulmonary rehabilitation.
Methodology
Design Study:
Randomized clinical trial
Study Population:
Patients with Heart failure and Chronic Obstructive Pulmonary Disease diagnosisStatistical Analysis
Descriptive analysis will be present as frequency and percentage if categorical variables and mean \& standard deviation if the variable is continuous with normal distribution; if not, it will report as median and percentiles (25-75). The normality distribution will be evaluated through a Shapiro-Wilk test.
At the beginning of the study, we will compare both groups to determine statistical significance differences. X2 will run in categorical variables and an independent t-study test in continuous variables with normal distribution, if not, U de Mann Whitney will be run.
To identifying the differences between groups along with the study, repeated analysis of variance measures will be done if the variable has a normal distribution. Otherwise, Friedman tests will be made. McNemar will be made for categorical variables. Furthermore, changes between groups along the time at student will be made with a normal distribution; otherwise, Wilcoxon will be done.
Alpha type error: it considered as a statistical significance a p\<0.05
Sample size A simple size space of 100 patients, 25 subjects per group will be included if prior consent is acquired, and they meet the inclusion criteria.
Procedures Invitation to participate All the patients who complete the inclusion criteria will be invited to the protocol. They shall be informed about the study, the possible risks and benefits of the treatment, and the possibility of leaving the study at any moment if the patients want. Those who accept participated will be enrolled in a list and then randomized into different groups of treatment.
Allocation to the treatment groups The allocation sequence will be generated in the site http://www.randomization.com; therefore, the patients will be assigned into one of the next groups: 1) control group 2)pulmonary rehabilitation 3) rehabilitation pulmonary group plus beta-hydroxy beta-methyl butyric (HMB) (4g) 4) pulmonary rehabilitation group plus Citrulline (4g). The cardiologist, nutritionist, the physic therapist, will be blinded to the assignation group treatments.
Baseline evaluation During the first evaluation, the clinical stage will be assigned, and the next valuations will be made: pulmonary function, endothelial function, exercise tolerance, functional class, signs, and symptoms. anthropometric and body composition indicators by electric bio-impedance, biochemical test, dietetics, handgrip strength Following visits All the patients, no matter the group, will have a follow up for three months. In the beginning, 6week later and finally at three months.
Survival follow-up wil be after two years treatment initiation
Heart Failure (HF) is a complex syndrome consequence of any structural or functional abnormality that impairs the capacity of filling or ejected of the heart. (1, 2).
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a progressive, systemic, and multi-organic disease with structural and functional changes, mostly in the lungs. It is characterized by a progressive limitation of airflow as a response to external factors such as airflow contamination, smoking, biomass, which are associated with chronic inflammation. (3).
Epidemiology
The cardiovascular disease is the leading cause of death worldwide (4); The HF prevalence goes from 1-2% in developed countries and increases to 10% in older \>70 years old.
COPD is an important global load affecting more than 600 million people corresponding to the 5 % off all cause of death worldwide (5).
Chronic Obstructive Pulmonary Disease and Heart Failure
COPD and HF are related between them, sharing the same risk factors and pathogenic mechanisms. They are growing in time and are epidemic diseases because of multiple factors. The cardiovascular disease takes an essential role in COPD, 30 to 50% of deaths are because of them; one of the most important is HF. COPD patients have three times the risk to developed HF (6), and between them, the risk of hospital readmission and death is higher than those without HF (7).
Nutritional Supplementation
β-Hydroxy-β-Methylbutyrate (HMB) HMB is a leucine metabolite, are a branch chain amino acid, and a regular potent in the muscular protein replacement and endogen sub-production that occurs in the muscles and liver. The first stage of change is through the transamination of the leucine to KIC, occurring in the mitochondrial and cytosol of the muscular cell. In the mitochondria, the KIC oxidates into isovaril-CoA, subsequently by other metabolism processes, it produces 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). Approximately 90% of KIC oxidize into isovaril CoA in the hepatic mitochondrial, lastly, acetoacetate and Acetyl-CoA. While the last 10% oxides into HMB in the cellular cytosol (8-10).
Supplementation with HMB
HMB develops a nutritional role; the daily supplementation has an anti-catabolic effect in the protein synthesis, increasing the muscular mass and diminished the muscular damage in adulthood.
Several studies evaluate the effects of supplementation with HMB, isolated, or combined in muscle functionality, strength, mortality, and indifferent pathologies(11). Recently, in a meth analysis and systemic review of randomized clinical trials made by Wu et al. to evaluate the effect of the administration with HMB over the corporal composition and muscular strength in adulthood in 65 years with pathologies. The study includes supplementation of HMB at 3mg doses at least eight weeks to increase the muscular strength and functionality (12). Supplementation with Ca-HMB with or without resistance exercise in older than 75 years' old was evaluated by Stout et al., in a pilot study, they made 2 phases: the first one (without exercise) supplementation with 3g of CaHMB vs. placebo and the second (with resistance exercise) with and without supplementation. They observed that the supplementation in the long term has better benefits, and increase lean mass, strength, quality, and functional muscle without exercise. In this study, they showed that there is no synergic effect with the exercise combined with supplementation (10).
Citrulline-arginine The principal precursor of citrulline is glutamine, representing 60% of the total synthesis of arginine de novo (13). Citrulline is released into the portal circulation because the enterocytes do not have the succinate arginine synthase. The liver absorbs one quantity in a normal hepatic function and goes to the systemic circulation and finally is transformed by the kidney into arginine (14). The supplementation is a potent nutrient-drug that helps to restore the arginine metabolism in different populations (14, 15).
Citrulline is considered a safe supplementation (16)with a maximum consumption of 15g/day and 13 g/day for arginine (17, 18). The blood levels in a healthy individual are 40 µmol/L (19). L citrulline increases the concentration of L arginine more efficiently than the supplementation of L-arginine; this is an amino acid, endogen precursor of the synthesis of oxide nitric (ON) (20).
Different studies with supplementation show a reduction in adhesion cells and leucocyte activation, as well as an improvement in endothelial function (21). Besides, in heathier subjects, it has been associated with less muscular fatigue, better VO2, and exercise tolerance. (22) In a randomized clinical trial (RCT) with healthy subjects, where they receive oral supplementation with citrulline, they showed an increase of 57% of the nitrogen balance 12 hrs. after (17)
Pulmonary rehabilitation
Pulmonary rehabilitation and physic therapy are essential components of the non-pharmacologic treatment, for HF and COPD, the guidelines' treatment recommends the pulmonary rehabilitation or physic therapy, to improve the exercise tolerance, skeletal and respiratory muscular function, also the quality of life of the patients (23, 24). On the other side, it has been demonstrated that pulmonary rehabilitation and physic therapy have benefits in the number of hospitalization and mortality of patients.
Ancanfora et al., in a randomized clinical trial evaluate the effect of cardiovascular training in patients with HF. The program consists of resistance activities and abdominal exercises, depending on the clinical characteristics of each patient, they were followed by four weeks, resulting in an improvement over-exercise tolerance, O2 maximum consumes and ventilatory threshold (25). Similarly, Keteyian et al., evaluated the physiological adaptation resulting by the physical training in patients with HF with Left ventricle ejection fraction. Also reduced the effects and security in clinical results, had a followed of 2-5 weeks, it consists by resistance exercises such as walking and the use of the static bicycle by 20-30 minutes (23). They conclude that the exercise was secure and improves the state of health, exercise capacity. O´connor et al., evaluated the effects of a regular aerobic exercise (bicycle, treadmill) in patients with HF plus the habitual care, followed by 30 months, they observed that the mortality and hospitalization decreases (26).
Additionally, Benefits have also been seen in patients with COPD; Petersen et al., after seven weeks, show that the resistance exercises twice a week improved exercise tolerance and diminished the fast degradation of proteins (27). Nevertheless, patients with HF and COPD have no guidelines that specified the type of exercise as well as the duration of it, or if there is a synergic effect with nutritional supplementation and which is the impact over the clinic stage.
General objective:
To assess the effect of nutritional supplementation and pulmonary rehabilitation on the clinical status of patients with HF and COPD compared to those subjects who do not receive nutritional supplementation or pulmonary rehabilitation.
Specific objectives
To evaluate the effect of pulmonary rehabilitation and supplementation over body composition in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over the exercise tolerance in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over pulmonary function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over endothelial function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over muscle function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
To evaluate the effect of pulmonary rehabilitation and supplementation over cognitive function in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
Evaluated the effect of nutritional supplementation and pulmonary rehabilitation over prognosis in COPD and HF patients compared to those subjects who receive non-pharmacology treatment based on guidelines treatment.
Hypothesis Subjects with HF and COPD who receive nutritional supplementation and pulmonary rehabilitation will have a better clinical status than those who do not receive nutritional supplementation or pulmonary rehabilitation.
Methodology
Design Study:
Randomized clinical trial
Study Population:
Patients with Heart failure and Chronic Obstructive Pulmonary Disease diagnosisStatistical Analysis
Descriptive analysis will be present as frequency and percentage if categorical variables and mean \& standard deviation if the variable is continuous with normal distribution; if not, it will report as median and percentiles (25-75). The normality distribution will be evaluated through a Shapiro-Wilk test.
At the beginning of the study, we will compare both groups to determine statistical significance differences. X2 will run in categorical variables and an independent t-study test in continuous variables with normal distribution, if not, U de Mann Whitney will be run.
To identifying the differences between groups along with the study, repeated analysis of variance measures will be done if the variable has a normal distribution. Otherwise, Friedman tests will be made. McNemar will be made for categorical variables. Furthermore, changes between groups along the time at student will be made with a normal distribution; otherwise, Wilcoxon will be done.
Alpha type error: it considered as a statistical significance a p\<0.05
Sample size A simple size space of 100 patients, 25 subjects per group will be included if prior consent is acquired, and they meet the inclusion criteria.
Procedures Invitation to participate All the patients who complete the inclusion criteria will be invited to the protocol. They shall be informed about the study, the possible risks and benefits of the treatment, and the possibility of leaving the study at any moment if the patients want. Those who accept participated will be enrolled in a list and then randomized into different groups of treatment.
Allocation to the treatment groups The allocation sequence will be generated in the site http://www.randomization.com; therefore, the patients will be assigned into one of the next groups: 1) control group 2)pulmonary rehabilitation 3) rehabilitation pulmonary group plus beta-hydroxy beta-methyl butyric (HMB) (4g) 4) pulmonary rehabilitation group plus Citrulline (4g). The cardiologist, nutritionist, the physic therapist, will be blinded to the assignation group treatments.
Baseline evaluation During the first evaluation, the clinical stage will be assigned, and the next valuations will be made: pulmonary function, endothelial function, exercise tolerance, functional class, signs, and symptoms. anthropometric and body composition indicators by electric bio-impedance, biochemical test, dietetics, handgrip strength Following visits All the patients, no matter the group, will have a follow up for three months. In the beginning, 6week later and finally at three months.
Survival follow-up wil be after two years treatment initiation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Heart Failure
Copd
Nutritional Supplementation
Pulmonary Rehabilitation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
TRIPLE
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Pulmonary Rehabilitation Group
Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
Group Type
ACTIVE_COMPARATOR
Nutritional supplementation and Pulmonary Rehabilitation
Intervention Type
DIETARY_SUPPLEMENT
Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Pulmonary Rehabilitation Group plus HMB (4g)
Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
Group Type
EXPERIMENTAL
Nutritional supplementation and Pulmonary Rehabilitation
Intervention Type
DIETARY_SUPPLEMENT
Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Pulmonary Rehabilitation Group plus citrulline (3g)
Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
Group Type
EXPERIMENTAL
Nutritional supplementation and Pulmonary Rehabilitation
Intervention Type
DIETARY_SUPPLEMENT
Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutritional supplementation and Pulmonary Rehabilitation
Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients that accept and signed the study consent.
* \> 40 years old
* Patients with Heart failure diagnosis confirmed by echocardiographic criteria according to the European Society of Cardiology guidelines (2).
* Heart failure patients in functional class I to III according to NYHA
* Patients with Chronic Obstructive Pulmonary Disease diagnosis according to GOLD guidelines with a post-bronchodilator spirometry VEF1/FVC index \<0.70 (50)
* \> 40 years old
* Patients with Heart failure diagnosis confirmed by echocardiographic criteria according to the European Society of Cardiology guidelines (2).
* Heart failure patients in functional class I to III according to NYHA
* Patients with Chronic Obstructive Pulmonary Disease diagnosis according to GOLD guidelines with a post-bronchodilator spirometry VEF1/FVC index \<0.70 (50)
Exclusion Criteria
* Patients with recent (\<3 months) exacerbations
* Terminal Chronic Renal Kidney Disease with a creatinine clearance \<30 ml/min/1.73m2
* Patients with a cancer diagnosis
* Patients with limitation to exercise
* Patients enrolled in another study protocol
* Terminal Chronic Renal Kidney Disease with a creatinine clearance \<30 ml/min/1.73m2
* Patients with a cancer diagnosis
* Patients with limitation to exercise
* Patients enrolled in another study protocol
Minimum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Enfermedades Respiratorias
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dulce González Islas, PhD
Researcher in Medical Sciences
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leslie Verdeja-Vendrell, M.Sc.
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas"
Dulce González-Islas, PhD
Role: STUDY_DIRECTOR
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas"
Arturo Orea-Tejeda, MD
Role: STUDY_DIRECTOR
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas"
Martha E Quintero-Martínez, B.Sc
Role: STUDY_CHAIR
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas"
Ilse C Pérez-García, B.Sc
Role: STUDY_CHAIR
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dulce González-Islas
Mexico City, Mexico City, Mexico
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Mexico
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009 Apr 14;119(14):e391-479. doi: 10.1161/CIRCULATIONAHA.109.192065. Epub 2009 Mar 26. No abstract available.
Reference Type
BACKGROUND
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1167. doi: 10.1016/j.rec.2016.11.005. No abstract available. English, Spanish.
Reference Type
BACKGROUND
Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65. doi: 10.1164/rccm.201204-0596PP. Epub 2012 Aug 9.
Reference Type
BACKGROUND
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
Reference Type
BACKGROUND
Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004 Sep 1;94(5):649-51. doi: 10.1016/j.amjcard.2004.05.034.
Reference Type
BACKGROUND
Rodriguez LA, Wallander MA, Martin-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010 Nov;104(11):1691-9. doi: 10.1016/j.rmed.2010.04.018. Epub 2010 May 18.
Reference Type
BACKGROUND
Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009 Dec;11(12):1182-8. doi: 10.1093/eurjhf/hfp148. Epub 2009 Nov 3.
Reference Type
BACKGROUND
Nissen S, Sharp RL, Panton L, Vukovich M, Trappe S, Fuller JC Jr. beta-hydroxy-beta-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. J Nutr. 2000 Aug;130(8):1937-45. doi: 10.1093/jn/130.8.1937.
Reference Type
BACKGROUND
Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults. J Nutr. 2001 Jul;131(7):2049-52. doi: 10.1093/jn/131.7.2049.
Reference Type
BACKGROUND
Stout JR, Smith-Ryan AE, Fukuda DH, Kendall KL, Moon JR, Hoffman JR, Wilson JM, Oliver JS, Mustad VA. Effect of calcium beta-hydroxy-beta-methylbutyrate (CaHMB) with and without resistance training in men and women 65+yrs: a randomized, double-blind pilot trial. Exp Gerontol. 2013 Nov;48(11):1303-10. doi: 10.1016/j.exger.2013.08.007. Epub 2013 Aug 24.
Reference Type
BACKGROUND
Fitschen PJ, Biruete A, Jeong J, Wilund KR. Efficacy of beta-hydroxy-beta-methylbutyrate supplementation in maintenance hemodialysis patients. Hemodial Int. 2017 Jan;21(1):107-116. doi: 10.1111/hdi.12440. Epub 2016 Jun 14.
Reference Type
BACKGROUND
Rahman A, Wilund K, Fitschen PJ, Jeejeebhoy K, Agarwala R, Drover JW, Mourtzakis M. Elderly persons with ICU-acquired weakness: the potential role for beta-hydroxy-beta-methylbutyrate (HMB) supplementation? JPEN J Parenter Enteral Nutr. 2014 Jul;38(5):567-75. doi: 10.1177/0148607113502545. Epub 2013 Sep 26.
Reference Type
BACKGROUND
Bahri S, Zerrouk N, Aussel C, Moinard C, Crenn P, Curis E, Chaumeil JC, Cynober L, Sfar S. Citrulline: from metabolism to therapeutic use. Nutrition. 2013 Mar;29(3):479-84. doi: 10.1016/j.nut.2012.07.002. Epub 2012 Sep 28.
Reference Type
BACKGROUND
Luiking YC, Poeze M, Ramsay G, Deutz NE. Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production. Am J Clin Nutr. 2009 Jan;89(1):142-52. doi: 10.3945/ajcn.2007.25765. Epub 2008 Dec 3.
Reference Type
BACKGROUND
Cynober L. Citrulline: just a biomarker or a conditionally essential amino acid and a pharmaconutrient in critically ill patients? Crit Care. 2013 Mar 11;17(2):122. doi: 10.1186/cc12534.
Reference Type
BACKGROUND
Rouge C, Des Robert C, Robins A, Le Bacquer O, Volteau C, De La Cochetiere MF, Darmaun D. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1061-7. doi: 10.1152/ajpgi.00289.2007. Epub 2007 Sep 27.
Reference Type
BACKGROUND
Grimble GK. Adverse gastrointestinal effects of arginine and related amino acids. J Nutr. 2007 Jun;137(6 Suppl 2):1693S-1701S. doi: 10.1093/jn/137.6.1693S.
Reference Type
BACKGROUND
Moinard C, Nicolis I, Neveux N, Darquy S, Benazeth S, Cynober L. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. Br J Nutr. 2008 Apr;99(4):855-62. doi: 10.1017/S0007114507841110. Epub 2007 Oct 22.
Reference Type
BACKGROUND
Papadia C, Sherwood RA, Kalantzis C, Wallis K, Volta U, Fiorini E, Forbes A. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007 Jul;102(7):1474-82. doi: 10.1111/j.1572-0241.2007.01239.x. Epub 2007 Apr 24.
Reference Type
BACKGROUND
Sureda A, Cordova A, Ferrer MD, Tauler P, Perez G, Tur JA, Pons A. Effects of L-citrulline oral supplementation on polymorphonuclear neutrophils oxidative burst and nitric oxide production after exercise. Free Radic Res. 2009 Sep;43(9):828-35. doi: 10.1080/10715760903071664. Epub 2009 Jul 6.
Reference Type
BACKGROUND
Bailey SJ, Blackwell JR, Lord T, Vanhatalo A, Winyard PG, Jones AM. l-Citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. J Appl Physiol (1985). 2015 Aug 15;119(4):385-95. doi: 10.1152/japplphysiol.00192.2014. Epub 2015 May 28.
Reference Type
BACKGROUND
Keteyian SJ. Exercise training in congestive heart failure: risks and benefits. Prog Cardiovasc Dis. 2011 May-Jun;53(6):419-28. doi: 10.1016/j.pcad.2011.02.005.
Reference Type
BACKGROUND
Acanfora D, Scicchitano P, Casucci G, Lanzillo B, Capuano N, Furgi G, Acanfora C, Longobardi M, Incalzi RA, Piscosquito G, Ciccone MM. Exercise training effects on elderly and middle-age patients with chronic heart failure after acute decompensation: A randomized, controlled trial. Int J Cardiol. 2016 Dec 15;225:313-323. doi: 10.1016/j.ijcard.2016.10.026. Epub 2016 Oct 11.
Reference Type
BACKGROUND
O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1439-50. doi: 10.1001/jama.2009.454.
Reference Type
BACKGROUND
Laratta CR, van Eeden S. Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int. 2014;2014:528789. doi: 10.1155/2014/528789. Epub 2014 Mar 2.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C68-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Exercise Training and Inflammatory Mediators in COPD
NCT03853174
COMPLETED
NA
Home-based Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease
NCT04722224
RECRUITING
NA
Home Pulmonary Rehabilitation for COPD
NCT03480386
COMPLETED
NA
Device-guided Breathing for Shortness of Breath in COPD
NCT01286181
COMPLETED
NA
Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity
NCT03836547
COMPLETED
NA
Effects of Pulmonary Rehabilitation on Respiratory, and Cardiovascular Functional Capacity in COPD
NCT02393469
UNKNOWN
NA
COPD and Inflammatory Mediators
NCT04271124
UNKNOWN
NA
Maintenance Schedules Following Pulmonary Rehabilitation
NCT00925171
UNKNOWN
PHASE2
Micro-doses of Physical Activity for COPD
NCT05553223
RECRUITING
NA
Physical Activity Intervention and Cardiovascular Risk Markers in COPD
NCT03869112
UNKNOWN
NA
TeleRehabilitation for Patients With Chronic Respiratory Failure.
NCT04566523
RECRUITING
Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD
NCT01682447
COMPLETED
NA
The Efficacy of Pulmonary Rehabilitation Exercise in Home Care for the Non-invasive Ventilator-dependent Elderly With COPD
NCT02836912
COMPLETED
NA
Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease
NCT06956742
RECRUITING
NA
Chronic Obstructive Pulmonary Disease (COPD) in Patients Hospitalized for Acute Decompensated Heart Failure.
NCT02340702
WITHDRAWN
Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)
NCT00982891
COMPLETED
PHASE2/PHASE3
Neuromuscular Fatigue During Exercise in COPD-HF Overlap
NCT05235685
RECRUITING
NA
Pulmonary Rehabilitation for Rural Patients With COPD
NCT06847061
RECRUITING
NA
Role of Oxygen in the Development of Fatigue in Patients With Chronic Respiratory Failure
NCT05533957
COMPLETED
NA
Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype
NCT01431625
UNKNOWN
PHASE4
Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD
NCT01909544
UNKNOWN
NA
Clinical Outcomes in Patients Referred to Pulmonary Rehabilitation
NCT03591263
UNKNOWN
Pulmonary Rehabilitation in the Chronically Critically Ill Patient
NCT06453421
RECRUITING
Digital App for Telerehabilitation in Respiratory Diseases
NCT05572346
UNKNOWN
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease
NCT01055730
COMPLETED